CCM
ABBV icon

CFO Capital Management’s AbbVie ABBV Stock Holding History

CFO Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$881K Sell
4,049
-6,660
-62% -$1.48M 0.73% 40
2025
Q4 		$2.45M Buy
+10,709
New +$2.44M 1.83% 15

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CFO Capital Management's ABBV Position: Q1 2026 in Review

CFO Capital Management reduced its AbbVie (ABBV) stake by 62% in Q1 2026, selling an estimated $1.48M and leaving 4,049 shares worth $881K. The position accounts for 0.73% of the portfolio, ranked #40.

CFO Capital Management first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.45M in Q4 2025. 4,091 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • CFO Capital Management held 4,049 shares of AbbVie worth $881K as of Q1 2026.
  • CFO Capital Management sold 6,660 AbbVie shares in Q1 2026, an estimated $1.48M.
  • AbbVie made up 0.73% of CFO Capital Management's portfolio in Q1 2026, its #40 holding.
  • CFO Capital Management first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
  • CFO Capital Management's AbbVie position peaked at $2.45M in Q4 2025.
  • 4,091 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on CFO Capital Management's 13F filing for Q1 2026, filed 4 May 2026.